Immediate Impact
1 from Science/Nature 59 standout
Citing Papers
Breast cancer: pathogenesis and treatments
2025 Standout
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
2024 Standout
Works of Elisa Picardo being referenced
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Elisa Picardo | 61 | 27 | 77 | 47 | 16 | 242 | |
| Charlotte H. J. R. Jansen | 79 | 19 | 81 | 36 | 16 | 221 | |
| E. Kent | 23 | 27 | 22 | 57 | 16 | 215 | |
| Shengfu Chen | 19 | 25 | 33 | 86 | 11 | 286 | |
| Samuel Dekermacher | 61 | 42 | 18 | 19 | 24 | 260 | |
| Giuseppe Zarbo | 39 | 22 | 104 | 12 | 19 | 258 | |
| Athanasios Pappas | 26 | 14 | 15 | 27 | 21 | 280 | |
| Chikako Ogawa | 40 | 4 | 75 | 131 | 22 | 252 | |
| Sabine Grill | 64 | 2 | 54 | 75 | 21 | 241 | |
| Outi Hirvonen | 64 | 36 | 25 | 48 | 21 | 293 | |
| Clara Castellucci | 18 | 5 | 60 | 32 | 13 | 202 |
All Works
Loading papers...